跳至主要内容
临床试验/NCT00156169
NCT00156169已完成3 期

The Effect of the Alga Dunaliella Bardawil as a Source of 9-cis Retinoic Acid

Sheba Medical Center0 个研究点目标入组 50 人开始时间: 2001年5月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
50

研究概览

简要总结

The effect of fibrates on high density lipoprotein (HDL)-cholesterol levels is suggested to be mediated by its binding to peroxisome proliferator-activated receptor-g (PPARg). Upon ligand binding, PPARg heterodimerizes with the 9-cis retinoic acid receptor (RXR), and the heterodimer regulates gene expression. We assessed the hypothesis that a dual treatment with fibrate plus 9-cis b-carotene-rich powder of the alga Dunaliella bardawil, as a source of 9-cis retinoic acid, would improve the drug's effect on HDL-cholesterol levels.

patients with plasma HDL-cholesterol levels below 40 mg/dl and triglyceride (TG) levels above 200 mg/dl after fibrate treatment (for at least 6 weeks). are given four capsules of Dunaliella, providing 60 mg b-carotene/day. The all-trans to 9-cis b-carotene ratio in the capsules is about 1:1.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
盲法
Double

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age 18-70 years
  • Fibrate treatment (for at least 6 weeks)
  • HDL-Cholesterol lower than 40mg/dl.
  • Triglyceride over 150mg/dl.

排除标准

  • High CPK.
  • Elevated liver functions.
  • Active CHD.
  • Diabetes patients treated with Insulin or Avandia. HbA1C great than 8.5.

研究者

申办方类型
Other Gov

相似试验